IRIDEX MicroPulse Technology Featured In Many Scientific Presentations at the European Glaucoma Society Meeting > IRIDEX

News

17

Mountain View Calif., May 16, 2018 -- IRIDEX Corporation(Nasdaq: IRIX) today announced that its products will be featured in five poster sessions covering data in a total of 68 eyes focused on open angle, mild to moderate and uncontrolled glaucoma at the 13th European Glaucoma Society Meeting (EGS) in Florence, Italy on May 19-22nd. The EGS is comprised of glaucoma care providers including glaucoma specialists, general ophthalmologists, optometrists, researchers, nurses, technicians, leaders of glaucoma and patient organizations.

The posters listed below will showcase IRIDEX MicroPulse technology. All posters will be available in the poster area.

Key Posters:

Monday, May 21, 2018

  • Cigdem Altan, MD: (P4.045) Early Clinical Outcomes of MicroPulse Transcleral Cyclophotocoauglation in Open Angle Glaucoma
  • Walid Zbiba, MD: (P4.081) MicroPulse Transscleral Cyclophotocoagulation in Glaucoma Management: The Tunisian Experience
  • Maria Cecilia Aquino, MD: (P4.097) External MicroPulse Diode Laser Trabeculoplasty for Primary Open Angles Glaucoma: A Pilot Study

Tuesday, May 22, 2018

  • Catherina Josephine Goenad, MD: (P5.016) Early Outcomes of MicroPulse Diode Transscleral Cyclophototherapy for Treatment of Mild to Moderate Glaucoma
  • Beatriz Rodriguez Aguado, MD: (P5.041) Transscleral Cyclophotocoagulation With Diode Laser for Refractory Glaucoma: Our Experience

IRIDEX will also be sponsoring a breakfast symposium titled, “MicroPulse therapy: a choice before, in combination with, and after any other glaucoma treatment.” The symposium will be held on Sunday, May 20th, during the 13th European Glaucoma Society Congress taking place May 19 – 22 in Florence, Italy. A distinguished panel of four ophthalmologists will present the science behind MicroPulse technology, their clinical experience with a variety of patient profiles, and the most recent data on outcomes.

“There is a significant increase in the amount of data regarding cyclophotocoagulation with MicroPulse technology. I am excited to share with my colleagues the versatility and success I have seen with the Cyclo G6 Glaucoma Laser System,” said Marc Toeteberg-Harms, MD, FEBO of Switzerland, who will be joined by Ziad Khoueir, MD, MSEd of Lebanon, Ronald de Crom, MD of The Netherlands, and Karin Roswitha Pillunat, MD of Germany for the one-hour reunion that will allow for questions and answers from the attendees.

About IRIDEX

IRIDEX is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. IRIDEX’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. IRIDEX products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit iridex.com/egs.

Media Contact:

Jamie Hall
Pascale Communications, LLC.
724.417.0167
jamie@pascalecommunications.com

Investor Relations Contact

Lynn Pieper Lewis or Leigh Salvo
415.937.5404
investors@iridex.com

Actions: E-mail | Permalink |
  • logo aa0
  • logo ags
  • logo ascrs
  • logo asrs
  • logo esrs0
  • logo euretina
  • logo LIGHT